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INTRODUCTION
The standard treatment approach in HIV-1 infec-
tion involves a combination of at least three anti-
retroviral (ARV) drugs, i.e. highly active anti-
retroviral therapy (HAART), to fully suppress the
plasma HIV-1 RNA viral load (VL). Currently, rec-
ommended first-line antiretroviral regimens con-
sist of two nucleoside (NRTI)/nucleotide (NtRTI)
analogue reverse transcriptase inhibitors com-
bined with a non-nucleoside reverse transcriptase
inhibitor (NNRTI) or a ritonavir-boosted protease
inhibitor (PI/r), or an integrase strand transfer in-
hibitor (INSTI). Furthermore, standard subse-
quent-line regimens involve an HAART approach,
with at least a triple combination of ARV drugs. 
For the first time, the Italian Guidelines on the
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use of ARV (I-ARVGL) published in the previous
issue of New Microbiologica introduced the con-
cept of LDR (Less Drugs Regimen), i.e. an ARV
treatment regimen involving fewer than 3 stan-
dard agents combined. This concept refers pri-
marily to an induction/maintenance therapy
strategy, namely a standard three-drug regimen
used to achieve virological suppression followed
by an LDR regimen to maintain viral control, al-
lowing at the same time the management of co-
morbidities, limiting or avoiding long-term tox-
icity, preserving future drug options, sometimes
reducing the daily pill burden improving adher-
ence and, consequently, improving the patient’s
quality of life.
The choice of suitable patients and the timing of
LDR initiation are critical to avoid virological fail-
ure and the emergence of resistant viruses. The
general considerations for a successful antiretro-
viral therapy with triple combination strategies
also apply for LDR:
– High viral load (>500,000 copies HIV-RNA/ml)
correlates with an increased risk of treatment
failure; 
– The combination regimen used should prefer-
ably have a high genetic barrier; 
– Archived resistance mutations in the mononu-
clear cells of peripheral blood are associated
with ARV treatment failure;
– The presence of virus with CXCR4 receptor
tropism is associated with a faster decline in
CD4+ T cells and disease progression;
– Compartmentalised virus with drug resistance
mutations in the central nervous system can
cause the failure either of first-line therapy or
the simplification strategies;
– High levels of viral DNA in circulating lym-
phocytes or residual viraemia are both asso-
ciated with virological rebound and failure of
simplification strategies.
Consequently, a detailed analysis of different set-
tings (naïve, stably-suppressed patients, viraemic
early-experienced patients, triple-class failure pa-
tients) and the possibility of using an LDR strat-
egy are described. The implications on pharma-
cological compatibility, co-morbidities, neu-
rocognitive aspects and patient-physician com-
munication are also explored.
The LDR strategy is the first ‘drug schematic sim-
plification’ step in a very long-term therapy ap-
proach that is currently available for HIV-1 pa-
tients in order to achieve wellbeing and disease
control. Changing treatment in this perspective
could be a feasible new option that needs to be
understood both by patients and physicians in
order to manage this life-threatening disease.
A multidisciplinary Italian Expert Panel on LDR,
composed of physicians, patients, payers, econo-
mists and institution members has reviewed all
HIV literature related to LDR and, on the basis of
own specific expertise, has developed statements
to define the right setting to use LDR strategies,
highlight potential benefits and define the limits.
To achieve this goal they followed a process which
included meetings, teleconferences and a final
workshop where all the Panel members shared,
discussed and voted all statements developed.
METHODOLOGY
The main aim of the final workshop was to dis-
cuss in a multidisciplinary setting the topic of
Less Drug Regimens in the context of HIV treat-
ment. The Steering Committee of the event was
composed of 10 Core Experts (CEs), who identi-
fied 6 thematic areas to be discussed:
– Virology;
– Therapeutic strategies;
– Drug toxicities;
– CNS protection and psychiatric distress;
– The role of communication in the patient and
doctor relationship in the context of LDR;
– Pharmacoeconomic and regulatory aspects.
Afterwards 6 Core Expert Clinician Groups
(CECGs) were organized, according to the 6 ar-
eas identified, composed of CEs (one or two per
area) and Expert Clinicians. The CECGs had the
task of identifying the scientific literature and
writing a draft of statements to be discussed dur-
ing the final workshop. Each CECG identified a
Research Fellow, having the role of scientific sec-
retariat for the coordination of the preliminary
work, and a Rapporteur, who was in charge of
presenting and explaining the statements during
the final workshop.
Statements were ranked according to (I-ARVGL).
Degree of recommendation (only positive state-
ments scored): 
a) Highly recommended; 
b) Moderately recommended; 
c) Optional. 
Level of evidence: 
1. Data obtained from at least one controlled,
randomized study with sufficient power or
from a meta-analysis of controlled studies; 
2. Data obtained from non-randomized studies
or from cohort observational studies; 
3. Recommendation based on case reviews or
expert opinion. 
At the final workshop 108 experts, mainly HIV
specialists, were invited. It was organised as fol-
lows: during the morning there were several main
lectures focusing on general issues related to HIV
infection and treatment, and the statements were
read by Rapporteurs. In the afternoon 6 Expert
Groups (EGs, one per area) were composed, in
which CECGs members and other HIV special-
ists analyzed the critical points, the pros and cons
of the strategy from every specific aspect and pre-
liminary discussed and possibly modified the
CECG drafted statements.
The following day, all 108 experts voted all the
statements of every area shown by Rapporteurs.
They were approved when at least 75% of partic-
ipants agreed with them; if agreements account-
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ed for less than 75%, statements went back to
EGs and were modified according to suggestions
of the panel to be voted again. They were defi-
nitely withdrawn in case of maintenance less than
75% agreement.
Naïve patients: studies, virological aspects
and strategic implications
The tailoring of the antiretroviral regimen is rec-
ommended to improve treatment outcomes in
HIV-infected patients. Several factors should be
considered when selecting a starting regimen. In
particular, the emergence of resistance mutations
and toxicities associated with NRTI and/or NNR-
TI represent a critical point in the selection of an
optimal antiretroviral regimen. The development
in clinical practice of dual therapies, based on the
use of PI/r + RAL or MVC may represent an al-
ternative to traditional regimens for long-term
management of HIV-infected individuals.
Consequently, a dual therapy including ritonavir-
boosted protease inhibitors (PI/r) may be a po-
tential and promising option also in antiretrovi-
ral treatment-naïve patients.
Several studies have investigated the efficacy in
naïve patients of dual therapies based on PI/r as-
sociated with 3TC (LOREDA with LPV/r), with
TDF (KALEAD with LPV/r), with efavirenz
(ACTG 5142 with LPV/r), raltegravir (SPARTAN
with ATV/r, PROGRESS and CCTG 589 with
LPV/r, ACTG 5262 with DRV/r, RADAR with
DRV/r) or with maraviroc (VEMAN with LPV/r;
A4001078 with ATV/r).
To date, the most important and convincing re-
sults have been obtained with LPV/r at week 96
(PROGRESS Study). Indeed, LPV/r plus RAL
showed non-inferiority versus the triple drug reg-
imen LPV/r + TDF/FTC and also a statistically sig-
nificant safer profile with regard to bone and re-
nal damage, lipoatrophy recover, despite the fact
that the lipid profile between the 2 arms after 96
weeks was similar.
A PI/r + MVC combination administered once a
day at low dosage (150 mg) in patients with R5
tropism was also investigated. The most inter-
esting data have been obtained with LPV/r at
week 96, in the VEMAN Study, whose prelimi-
nary viro-immunological results are extremely
encouraging.
In the ACTG 5142 Study, the LPV/r + EFV com-
bination was very potent, but unfortunately re-
vealed two major limitations of certain NRTI-
sparing strategies: toxicity and the development
of resistance.
Atazanavir does not seem to be the best compan-
ion either for maraviroc or raltegravir. Indeed, al-
though the agent was unboosted and administered
as 300 mg twice daily, results obtained in 2 ran-
domised trials, the A4001078 and SPARTAN stud-
ies, showed that NRTI-sparing arms were inferi-
or to standard care, in the former case as regards
potency and in the latter as regards toxicity. 
As far as darunavir is concerned, a preliminary
single arm study, ACTG A5262, raised some con-
cerns regarding the potency of the darunavir/r
(800/100 mg) + raltegravir combination, espe-
cially in patients with a baseline HIV-RNA greater
than 100,000 copies/mL. Moreover, darunavir
CSF concentrations in patients taking the once-
daily or the twice-daily dosage of the drug are dif-
ferent: recent data show that darunavir and ri-
tonavir dosing not only significantly affects CSF
concentrations, but also the extent of drug pene-
tration into CSF in the once-daily dosage.
Monotherapy with PI/r is not currently recom-
mended in naïve patients, as supported by the
MONARK and ACTG A5262 studies.
Statements
The general rationales for the use of a PI/r as the
backbone component of a dual regimen in anti-
retroviral-treatment-naïve patients are: high ge-
netic barrier, sequenceability, pharmacokinetics,
immunological T CD4+ recovery and tolerability.
– Considering its uniquely high genetic barrier,
a PI/r should always be included in an initial
dual regimen (AI). 
– Dual therapies, based on the use of PI/r + RAL
or MVC, represent a potential option for treat-
ment of naïve patients at risk of NRTI toxici-
ty and in the presence of NRTI resistance mu-
tations (BII). In particular, dual therapy with
lopinavir/r + RAL (AI) or MVC (BI) may be
considered.
– Monotherapy should be discouraged.
Stably-suppressed patients: studies, virologi-
cal aspects and strategic implications
The positive dramatic impact of highly active an-
tiretroviral therapy (HAART) can be compensat-
ed by the entity of side-effects either at mid- and
long-term and “therapeutic tiredness”. These side-
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effects are mainly due to NRTI and NNRTI ex-
posure and could have an impact on long-term
adherence. A complex interaction between the
various elements, linked to both virus and host,
could potentially lead to virological failure and
drug resistance. The main aims of LDR include
maintaining virological suppression and the long-
term efficacy of HAART.
Potency and high genetic barrier are the main
factors supporting the use PIs/r within LDR sim-
plification regimens (both mono- and dual-ther-
apy). The true backbone role of PIs/r is reflected
in their capacity to drastically reduce HIV-RNA
and not exclusively in their intrinsic antiviral ac-
tivity. Their role in LDR simplification regimens
cannot be matched by other compounds belong-
ing to other classes in clinical use, such as inte-
grase or CCR5 inhibitors. With this in mind, the
activity of various inhibitors can be described by
the equation: LPV/r = DRV/r > ATV/r.
None of the data available, often of poor quality
and/or not recent, analyze cellular DNA or resid-
ual viraemia trends. Their role of these parame-
ters in allowing the identification of patients eli-
gible for switching, and the evaluation of the po-
tency of all these treatment combinations have
to be extrapolated from other therapeutic set-
tings, such as treatment-naïve (MONARK study)
or monotherapy-experienced patients. CD4+
nadir, plasma viraemia zenith and therapy dura-
tion with suppressed viraemia are common pre-
dictors of success, but need further validation.
Monotherapy
Extensive experience with LPV/r, particularly in
the OK04 Study, and with DRV/r in the MONET
and MONOI studies (different dosages analyzed)
were seen to maintain HIV-RNA <50 cp/mL in
subjects with suppressed viraemia at the start of
monotherapy and absence of protease resistance
associated mutations (RAMs) in previous geno-
types. This makes LPV/r and DRV/r the drugs of
choice for monotherapy in HIV-1 management,
on account of their very high genetic barrier. 
Virological control in subjects treated for a certain
number of years should be the sine qua non con-
dition for simplifying an antiretroviral regimen.
This consideration is the main obstacle to a
broader use of PI/r monotherapy by clinicians.
Good candidates for starting PI/r monotherapy
are subjects with an undetectable HIV-RNA <50
cp/mL (“the lower the better”) at the beginning
of the strategy, who are fully adherent as seen
during previous triple-drug regimens and who
have been successfully treated for at least the last
12 months.
The extent of the HIV blood reservoir, measured
as HIV-DNA, constitutes the potential viral span
that could expand upon insufficient drug pres-
sure. A lower cell-associated HIV load can
favourably maintain viral suppression once PI/r
monotherapy is started.
Dual therapy
PIs + RAL
Few studies have been published on suppressed
patients switched to dual therapy containing PIs
and RAL. A non-random-retrospective trial is
available on 20 highly treatment-experienced pa-
tients who switched to ATV + RAL and were fol-
lowed for 18 months. Five (25%) patients were
switched before 12 months but maintained viral
suppression. 
In a 48-week single-centre, open-label pilot study
in which 60 HIV-infected adults with plasma HIV-
1 RNA (<50 copies/mL) on stable HAART
(sHAART) were randomised (2:1) to lopinavir/ri-
tonavir (LPV/r) 400/100 mg BID + raltegravir
(RAL) 400 mg BID switch (LPV/r + RAL arm) or
to continue on sHAART. The primary endpoint
was the proportion of subjects with HIVRNA<50
copies/mL at week 48. Secondary efficacy, im-
munological and safety endpoints were also eval-
uated.
Demographics and baseline lipid profile were
similar across the arms. Mean entry CD4 T-cell
count was 493 cells/mm3. At week 48, 92% (95%
confidence interval (CI): 83%-100%) of the LPV-
r/RAL arm and 88% (95% CI:75%-100%) of the
sHAART-arm had HIV-RNA<50 copies/mL
(p=0.70). Lipid profile (Mean ± SEM, mg/dL,
LPV/r + RAL vs. sHAART) at week 24 was: total-
cholesterol 194±5 vs. 176±9 (p=0.07), triglycerides
234±30 vs. 133±27 (p=0.003), and LDL-choles-
terol 121±6 vs. 110±8 (p=0.27). There were no se-
rious adverse events (AEs) in either arm. Regimen
switch occurred in 3 LPV/r + RAL subjects (n=1,
due to LPV/r + RAL related-AEs) vs. 0 in the
sHAART arm. There were no differences between
arms in bone mineral density, total body fat com-
position, creatinine clearance, or CD4+ T-cell
counts at week 48. In virologically suppressed pa-
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tients on HAART, switching to the NRTI-sparing
LPV/r + RAL combination produced a similar
sustained virological suppression and immuno-
logical profile as sHAART (KITE Study). 
PIs + MVC
As far as MVC use is concerned, despite the rela-
tive abundance of data on naïve patients, little
published data are available for suppressed sub-
jects. The need for tropism testing before use of
MVC in patients with suppressed viral replication
may be overcome by the analysis of stored plas-
ma HIV-1 RNA collected prior to suppression, or
the use of proviral DNA obtained from PBMCs.
Recent studies demonstrated a good correlation
between tropism predictions from proviral DNA
and results derived from viral RNA, however da-
ta from large cohorts and the overall clinical util-
ity of this assay have yet to be determined. 
Vitiello et al. published a small dataset on 20 sup-
pressed subjects who switched to MVC-contain-
ing regimens and were studied for six months.
Seven subjects were switched to MVC + DRV/r
and one to DRV, and only one patient showed a
rebound 4 months after switching from TDF,
LPV/r and saquinavir to MVC+DRV/r therapy. The
observation that the other subjects maintained a
VL below 50 copies/mL after switching provides
initial support for using proviral DNA to assess
viral tropism.
The MVC dosage when used with a boosted PI, as
derived primarily from the MOTIVATE trial, is
150mg BID. Nevertheless, pilot studies on naïve
patients on dual therapy with a single MVC dose
(300 mg or 150 mg) combined with LPV/r and
ATV/r are available. 
Due to boosting that completely abolishes liver
excretion, meaning that the drug is completely
excreted through the kidneys, MVC can be ad-
ministered in dual therapy with a boosted PI at
300 mg od or at 150 mg qd if creatinine clearance
is <80 ccs/min.
PIs + NNRTIs
The ATV + NVP combination has been tested in
local experiences, but showed an unsatisfactory
pharmacokinetic profile. 
Switching to a nucleoside-sparing regimen of
nevirapine + lopinavir/r in 34 subjects (compared
to 33 with PI/r plus two NRTI) maintained full
antiviral efficacy over 12 months, and suggests a
reversion of nucleoside-associated mitochondri-
al toxicity. This association may be an option for
avoiding mitochondrial toxicity (MULTINEKA
Study). 
One randomised, open-label study was per-
formed on 236 patients who had virological sup-
pression for ≥18 months and were switched to
LPV/r BID + EFV or EFV + 2 NRTIs. After 2.1
years of follow-up, fewer drug-related toxicity
discontinuations were reported and a trend to-
ward a higher virological failure (VF) rate was
seen with LPV/r + EFV in intention-to-treat and
as-treated analyses.
Due to its high genetic barrier, etravirine (ETV)
could be the best NNRTI to be used in combina-
tion with a PI/r in suppressed patients, however
data on this combination in dual therapy are lack-
ing. Adding ETV to a salvage regimen containing
darunavir/r (DRV/r) significantly increased the
probability of virological success, reducing and
limiting the onset of PI-related resistance muta-
tions in the DUET trials. Following these consid-
erations and given the need to reduce long-term
toxicity in treated patients, studies on dual com-
binations including ETV plus a potent PI/r (LPV/r,
DRV/r and ATV/r) are urgently needed, taking in-
to consideration PK interactions according to
ETV available data.
PIs + NRTI (or NtRTI)
The only data available for this strategy concern
switching to lamivudine (3TC) plus atazanavir/r
(ATV/r). The ATLAS study demonstrated a sus-
tained suppression of HIV viral load at 24 weeks
after switching to 3TC plus ATV/r, with steady
lipid tests and renal function improvement. 
The efficacy of dual therapy including 1 NRTI
and 1 PI/r was also tested in antiretroviral-naïve
patients. The LOREDA pilot study demonstrated
the efficacy of LPV/r + 3TC in suppressing HIV vi-
ral load in naïve patients, achieving >80% sup-
pression in “as treated” analysis. 
The KALEAD trial demonstrated similar efficacy
when comparing co-formulated TDF/FTC plus
LPV/r vs TDF alone plus LPV/r in naïve patients.
Higher CD4+ increase and fewer metabolic dis-
orders were also observed in the TDF-only arm.
Statements
– Monotherapy with a PI/r is indicated for HIV+
subjects who are virologically suppressed and
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clinically stable under antiretroviral treatment
(BI). This evidence comes from studies with
LPV/r (BI) and DRV/r (BI), but not for ATV/r.
– Dual Therapy - NRTI sparing strategies -
should always include a PI/r plus an NNRTI
(BIII), raltegravir (AIII), or maraviroc (AIII).
– Dual therapy including 3TC/FTC and 1 PI/r can
be used as an alternative to PI/r monotherapy
when the latter strategy is not indicated (i.e.
low CD4+ nadir, CNS involvement, etc.) (BII). 
– In patients with Hepatitis B co-infection, the
use of tenofovir (TDF) as single NRTI in com-
bination with a PI/r is mandatory (AII).
– In stable patients with NRTI-associated toxi-
cities, PI/r-based LDR can be considered both
as monotherapy (BI) and dual therapies (BI-
II).
– PI/r are the key drugs for avoiding the emer-
gence of cross-resistance due to their high ge-
netic barrier (AI). 
– Based on available data, monotherapy with
PI/r should be reserved (AII) for patients with:
• No history of virological failure or major
mutations of resistance to PI/r.
• Suppression to <50 copies/mL for more
than twelve months under continuous
treatment.
• CD4+ count greater than 200 cell/mm3 at
the time of the switch to simplification.
• Nadir >100 cell/mm3.
• Optimal adherence.
– LDR can be also considered as a treatment op-
tion for pre-emptive switch in an induction-
maintenance strategy in patients who started
or included a PI/r (BII) in the presence of a
stable immunovirological profile.
Viraemic, early-experienced patients (from
1st - 2nd lines): studies, virological aspects
and strategic implications
Current guidelines state that the goal of therapy
is to achieve and maintain HIV-1 RNA below de-
tectable levels, with recommendations to change
regimens upon virological failure because of the
adverse consequences of higher levels of viraemia
and viral evolution. Italian guidelines strongly
recommend changing the regimen with at least 2,
or, even better, 3 drugs, that are fully active in fail-
ing patients with viraemia >1000 copies/mL and
genotypic resistance (AII); moderately recom-
mend a regimen modification in patients with vi-
raemia >1000 copies/mL without genotypic re-
sistance mutations and in patients with persistent
viraemic blips (BII), and do not recommend reg-
imen modification in patients with isolated vi-
raemic blips.
One major concern regarding the use of PI/r
monotherapy is the potential for loss of control of
compartmentalised virus in the cerebrospinal flu-
id or other sanctuary sites. For this reason, dual
therapy companion drugs should have a high cen-
tral nervous system penetration-effectiveness
score.
One randomized multicenter study (HIV-STAR
Study) using mono-LPV/r vs. TDF/3TC/LPV/r as
second-line therapy in HIV-infected adults fail-
ing NNRTI-based HAART showed that at 48
weeks the proportion of patients with HIV-RNA
<400 copies/ml in the mono-LPV/r-arm was 75%
vs. 86% in the TDF/3TC/LPV/r-arm (p=0.053). The
authors concluded that LPV/r monotherapy
should not be recommended as a second-line reg-
imen, or should be used with caution particular-
ly in those settings where close VL monitoring is
not available. 
In the LDR setting, dual therapy including PIs/r
could also be a suitable option in patients expe-
riencing a first (or second) virological failure in
the absence of any previous PI failure. In the
event of documented NRTI toxicity, the rationale
for the use of a PI/r as the backbone component
of dual regimen is the high genetic barrier, toxi-
city, CD4+ recovery and few or no PI mutations
detected at failure. However, these benefits may
be overwhelmed by virological breakthroughand
the development of resistance mutations to the
companion drugs (efavirenz or raltegravir), there-
by reducing the ability to keepdrugs or drug class-
es for future use.
Statement
For patients who failed their first (or second) reg-
imen of 2 NRTI + 1 NNRTI, or 3 NRTI with no
previous treatment failure to PI, dual therapies
(based on the use of PI/r +RAL or +MVC for pa-
tients infected with R5 HIV-1) represent a poten-
tial treatment option (BIII). 
Triple Class Failure (TCF) patients: studies,
virological aspects and strategic implications
Building an effective salvage therapy must pri-
marily be based on potency and genetic barrier,
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and consequently a boosted PI is normally part of
any dual drug salvage regimen. Sensitivity to the
class accompanying the boosted PI should be
warranted by lack of previous use and by co-re-
ceptor tropism analysis as recommended by cur-
rent guidelines. If a CCR5 antagonist is consid-
ered, a low nadir CD4+ count should be viewed as
a proxy for past X4 virus even if current R5 tro-
pism is demonstrated. On the other hand, sensi-
tivity to the boosted PI should be supported by
cumulative analysis of all available HIV genotypes
and a particularly careful review of patient treat-
ment history. Indeed, the extent of previous ex-
posure to PIs has been shown to be an inde-
pendent predictor of triple salvage treatment fail-
ure in observational studies, including large
datasets of cases used to validate genotypic re-
sistance interpretation. 
There is some indirect evidence that dual thera-
py based on a boosted PI plus an integrase in-
hibitor can be an effective rescue strategy in pa-
tients harbouring virus expected to be complete-
ly resistant to NRTI and NNRTI. However, resid-
ual activity of NRTI genotypically deemed inef-
fective has also been inferred in this context. By
contrast, the contribution of inactive NRTI ap-
pears to be negligible when added to a three-drug
salvage strategy or removed from triple therapy in
the context of prolonged suppression of virus
replication.
One plausible scenario where dual therapy based
on a boosted PI plus an INI or a coreceptor an-
tagonist (CA) is expected to be effective is previ-
ous failure to NRTI plus NNRTI therapy. When
building a dual therapy regimen in this case, the
same guiding principles derived from studies
evaluating boosted PI plus INI/CA therapy in
drug-naïve patients should be applied (e.g. pos-
sibly differential activity of different PIs combined
with INI/CA).
Dual therapy can be considered in individual cas-
es, particularly when toxicity issues and multiple
previous failures discourage the use of several an-
tiretroviral drug classes. 
TCF is frequently associated with severe immun-
odeficiency and an immediate risk of disease pro-
gression, therefore the main goal in this setting is
to achieve rapid control of viral replication and
robust CD4 recovery. Preliminary data suggest
the possibility of prescribing, even for TCF pa-
tients, effective and well-tolerated NRTIs and/or
PI/r sparing regimens. Nevertheless PI/r are cur-
rently the salvage regimens of choice for the vast
majority of patients. 
Dual drug salvage therapy should only be used in
cases where a boosted protease inhibitor (PI) is
expected to maintain complete or substantial ac-
tivity. Use of a high genetic barrier regimen based
on a boosted PI is indeed recommended since the
dual drug salvage regimen will most probably in-
clude a new but less robust drug class such as an
integrase inhibitor (INI), a coreceptor antagonist
(CA) or a fusion inhibitor (FI).
Statements
– Monotherapy is not a feasible option and dual
therapy is not generally recommended as sal-
vage or deep salvage treatment. 
– A dual PI/r-based regimen may be considered
as a simplification strategy in TCF patients
who have reached undetectability with the
crucial goals of reducing toxicities and saving
options for the future (CII). In this case, the
maintenance of fully susceptible agents in the
regimen and a strict virological follow-up of
the patient are mandatory (AII). 
– In the presence of three active drugs belong-
ing to other classes, use of NRTIs in salvage
regimens is unnecessary, due to the extensive
degree of resistance to this class (BII). 
Pharmacological compatibility
The compatibility of the drugs combined in a reg-
imen is a key factor for therapeutic success, and
this is particularly true for LDRs. One aspect of
drug compatibility is pharmacokinetic symme-
try, meaning a substantial equivalence of the half-
lives of the drugs in the regimen. In the SPAR-
TAN study, where raltegravir was administered
in combination with unboosted atazanavir (at the
unusual dosage of 300 mg BID), an increased risk
of selection of raltegravir resistance mutations
was observed in patients with virological failure.
This was thought to be related to the combina-
tion of the short half-life of unboosted atazanavir
and the prolonged half-life of raltegravir
(atazanavir is known to increase raltegravir con-
centration by 40-70%), leading to residual ralte-
gravir monotherapy in the case of missed doses,
and consequent increased risk of selection of re-
sistance mutations.
It must be recognized that as long as adherence
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is optimal there are no reasons for predicting
treatment failure, regardless of pharmacokinetic
compatibility (symmetry), while the problem
emerges whenever drugs are no longer properly
taken, and the residual persistence of drug con-
centrations following interruption is unbalanced,
with a substantial risk of prolonged monothera-
py with decreasing concentrations over time. The
prototype of such a situation is represented by
the NRTIs-sparing arm of the ACTG 5142 trial. 
A second aspect of pharmacological compati-
bility is the lack of clinically significant drug-
drug interactions. A couple of studies suggest-
ed that raltegravir decreases darunavir concen-
trations, however other pharmacokinetics stud-
ies showed the magnitude of this interaction to
be negligible. The results of the ACTG 5262 tri-
al, in which excess virological failure was ob-
served in patients starting darunavir/r plus ral-
tegravir treatment with a high baseline viral
load, suggested that this interaction may play a
role. However, pharmacokinetic analyses did not
support any relationship between the risk of fail-
ure and darunavir concentrations. The reason
for this unexpected failure rate could be related
to the combination of poor patient compliance
and limited forgiveness of the regimen contain-
ing raltegravir plus a boosted PI (not necessari-
ly only with darunavir). However, data from
large clinical studies (NEAT 001) are expected
in the near future.
A second example is the compatibility between
etravirine and PIs: interaction studies and clini-
cal practice suggest a possible association with
darunavir and lopinavir, but not with atazanavir,
due to the significant decrease in the plasma ex-
posure of the latter, however clinical data are still
lacking. Furthermore, due to the significant dif-
ference in the elimination half-life between
etravirine and PIs/r, etravirine monotherapy
seems likely to occur in case of treatment inter-
ruption. Although etravirine has a stronger ge-
netic barrier than first-generation NNRTIs, it does
not mean that it can be taken into consideration
in a setting of monotherapy.
A third aspect of pharmacological compatibility
concerns the adequate dosing of drugs. It was re-
cently suggested that maraviroc should be dosed
at 150 mg qd when combined with a boosted PI,
accordingly to a reanalysis of the MOTIVATE tri-
al. In the pharmacokinetics sub-studies of two
randomised pilot trials, maraviroc at 150 mg qd
showed adequate plasma exposure when associ-
ated with lopinavir/r and atazanavir/r. However,
broader clinical evaluation is required.
Darunavir CSF concentrations in patients taking
the 800/100 once-daily or the 600/100 twice-dai-
ly dosage of the drug are different: recent data
show that darunavir and ritonavir dosing not on-
ly significantly affects CSF concentrations, but al-
so the extent of drug penetration into CSF in the
once-daily dosage. This different CSF concentra-
tion also correlates with a statistically higher
number of CSF escapes with 800/100 QD dosage
vs 600/100 BID dosage. Interestingly, patients re-
ceiving darunavir/r QD showed not only lower
CSF darunavir trough concentrations but also
lower CPRs. An explanation for this could be the
dose-dependant ritonavir inhibition of trans-
porters present at the BBB. These findings might
also be of interest in the light of the increasing
attention being paid to DRV/r monotherapy, and
especially to the doubts still concerning its activ-
ity into the CNS.
In conclusion, the status of current knowledge
on the pharmacological compatibility of PI-con-
taining dual regimens are in favour of LPV/r (with
RAL 400 mg BID, MVC 150 mg QD, ETV 200 mg
BID, 3TC 300 mg QD). Positive data are also
available for DRV/r and ETV 200 mg BID, 3TC
300 mg QD (not with RAL 400 mg BID). Positive
data are available for ATV and MVC 150 mg QD
and 3TC 300 mg QD. Data on possible PI-spar-
ing dual regimens (e.g, raltegravir and nevirap-
ine) are still missing.
Statements
– PI/r monotherapies guarantee pharmacologi-
cal exposure of the protease inhibitor compa-
rable to that obtained in triple regimens (AII).
– When a dual therapy is chosen, the drugs’
pharmacological compatibility should be con-
sidered (BII).
Co-morbidities
Cardiovascular aspects
Given the known association between NRTI (timi-
dine analogues and d-drugs) and metabolic al-
terations (metabolic abnormalities and hepatic
steatosis) it has been hypothesised that an alter-
native nucleoside analogue or a NRTI-sparing
regimen could reduce CV risk. The other nucleo-
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side backbones, based on ABC or TDF, cannot al-
ways be used as an alternative due their toxicity
profiles. Concern has also been expressed re-
garding the potential CV risk associated with NR-
TI, and particularly with abacavir, however the
potential mechanisms of this signal are not con-
clusive to providing a final answer. 
Contrary to expectations, a significant worsening
in lipid metabolism was seen in patients switch-
ing from TDF/FTC to the IP/r monotherapy arm
(MONOI, MONET, MONARK). There were no
statistically significant differences in the mean
change from baseline to week 96 in lipid param-
eters in patients in LPV/r+RAL (PROGRESS
study) or MRV (VEMAN study) vs. triple regi-
mens LPV/r +FTC+TDF.
A recent analysis of Abbott clinical trials based
on 3454 patients and pharmacovigilance do not
suggest that rates of MI and CAD during LPV/r
use are significantly elevated relative to the rate
observed in the general American population. No
study was able to show a significant change in
FMD compared to baseline.
Liver
Several drugs should be used with caution in pa-
tients with underlying liver diseases. Thymidine
analogue and zidovudine appear to have the high-
est risk of drug-induced liver damage, particu-
larly in patients with viral hepatitis and /or NASH.
Given the known association between NRTI (timi-
dine analogues and d-drugs) and hepatic steato-
sis, it has been hypothesised that an alternative
nucleoside analogue or a NRTI-sparing regimen
could reduce hepatic toxicity. PI/r monotherapy +
LPV/r + anti-HCV drugs have been shown to be
as safe and efficacious as HAART + anti-HCV
drugs (KAMON 2 Study).
Raltegravir has been shown to have a good liver
safety profile in HIV/HCV patients. HCV co-in-
fection is associated with an increased risk of
HIV-related kidney disease, including proteinuria
and acute renal failure, than HIV monoinfection.
Kidney
One recent publication evaluated the relationship
between cumulative and overexposure to teno-
fovir and kidney outcomes in 10,841 HIV-infect-
ed patients from the Veterans Health
Administration, who initiated antiretroviral ther-
apy between 1997 and 2007. Tenofovir exposure
was independently associated with an increased
risk for three types of kidney events and did not
appear to be reversible.
In the EUROSIDA cohort study on 6843 HIV-pos-
itive subjects with at least three serum creatinine
measurements and corresponding body weight
measurements from 2004 onwards, increasing
exposure to tenofovir was associated with a high-
er incidence of CKD, as was true for indinavir
and atazanavir, whereas the results for lopinavir/r
were less clear.
The association with a boosted PI is important
to guarantee adequate virological efficacy (al-
though boosted atazanavir should be used only
in the absence of other treatment options). Recent
data show atazanavir to be potentially nephro-
toxic, most likely due to tubulo-interstitial dam-
age secondary to an indinavir-like cristalluria phe-
nomenon. 
Although there are no conclusive data regarding
the toxicity of the new molecules (maraviroc and
raltegravir), results achieved in published stud-
ies (MERIT, 004, SWITCHMRK) do not demon-
strate renal toxicity.
A dual therapy study using lopinavir/r plus ralte-
gravir (PROGRESS) was also seen to be kidney-
friendly: eGFR reduction statistically significant.
The use of 3TC in dual therapy regimens is not
currently supported by specific toxicity studies,
however its use in these settings could be con-
sidered reasonable, given its widely accepted tol-
erability profile. 
Monotherapy LDRs based on potent boosted PIs
and low renal toxicity are a plausible option.
In the KITE study, the baseline mean CrCL was
statistically significantly higher for LPV-r/RAL pa-
tients than sHAART patients (p=0.02). Among 28
subjects whose baseline sHAART regimen in-
cluded TDF (n=17 in LPV-r/RAL and n=11 in
sHAART),baseline adjusted CrCL (mean + SEM)
in sHAART and LPV-r/RAL arms respectively, was
107+4 mL/min and 114+5 mL/min (week-2),
107+4 mL/min and 114+5 mL/min (week 24), and
111+6 mL/min and 117 + 7 mL/min (week-48),
and did not significantly differ between arms.
Bone
HIV-infected patients had an increased risk of
fracture compared to population controls.
Moreover, the 10-year incidence of bone fractures
was 3.6-fold higher in HCV co-infected patients.
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Studies currently available concerning LDR
(PROGRESS, MONET) show better performance
on bone homeostasis in patients with backbone-
sparing regimes, especially with regard to BMD
and vitamin D.
The PROGRESS study at 96 weeks found a sig-
nificantly reduction in BMD in patients taking
LPV/r + RAL than those who received LPV/r +
TDF/FTC.
Switching to raltegravir is associated with in-
creases in total body BMD.
The SMART study showed a partial reversibility
in bone damage in patients who stopped ARV.
Combination ARV therapies that include TDF
have been shown to lead to an increased risk of
inducing fracture. 
TDF use, PI use, TNF-alpha activity and advanced
HIV disease are associated with changes in bone
turnover markers, highlighting the complicated
interaction between ART, bone turnover, inflam-
mation and immune status, which extend beyond
the OPG/RANKL system.
Body changes
Pre-emptive or reactive switching from thymi-
dine analogues (stavudine or zidovudine) to al-
ternative nucleoside analogue agents or to a NR-
TI-sparing regimen was seen to cause modest
gains in limb fat.
Cumulative exposure of thymidine analogue nu-
cleoside reverse transcriptase inhibitors (stavu-
dine and, to a lesser extent, zidovudine) is strong-
ly associated with the development of lipoatrophy 
A shift from lipoatrophy to lipohypertrophy is ob-
served in the HAART era parallel to a reduction
in the use of thymidine analogue nucleoside re-
verse transcriptase inhibitors and aging of the
HIV population.
Switching from TDF/FTC to PI/r monotherapy is
associated with an increase in limb fat.
At 96 weeks, a significant sparing of peripheral
lipoatrophy was noted in the lopinavir/ritonavir
monotherapy simplification strategy compared
to an EFV-based triple regimen. 
There are conflicting data on the role of the dif-
ferent PIs/r with regard to the benefit they have
on lipoatrophy improvement.
In the ACTG 5142 study, lipoatrophy was less fre-
quent for patients taking LPV/r than for patients
taking EFV. In particular, EFV was associated
with a 2.7 times higher risk of developing lipoat-
rophy when used with 2 nukes compared to
LPV/r when used with 2 nukes. This difference
was not affected by which nukes were used.
Progress study: 96 wks lipoatrophy recover.
ATV/r has been associated with greater central
fat gain than EFV.
Switch from LPV/r regimens to ATV/r regimens in
virologically suppressed HIV-infected adults, was
associated with greater and statistically signifi-
cant trunk fat, both subcutaneous and visceral.
The percentage of patients with an increase of
20% in total fat was 37.8% and 15.2% in the ATV/r
and LPV/r groups, respectively (p¼0.018). In the
ATV/r group, the increase in trunk fat (9.4%) was
significantly higher than in peripheral fat (3.7%)
(p¼0.007), leading to a significant increase in fat
mass ratio (3.76%, p¼0.028), whereas no signif-
icant differences were found among LPV/r pa-
tients. CT scans showed that abdominal fat in-
crease corresponded to both visceral (28%,
p¼0.008) and subcutaneous fat (42%, p¼0.008).
Switching from a protease inhibitor to a NNRTI
or abacavir did not lead to any improvement in
lipohypertrophy
Lipodystrophy is uncommon for new ARV drugs
(CCR5 and integrase inhibitors). 
Mitochondrial toxicity
Mitochondrial toxicity drives long-term toxicities
associated with cumulative exposure to NRTI, in
particular with thymidine and adenosine ana-
logue NRTIs, such as ZDV, d4T and ddI.
The clinical presentation of NRTI toxicity de-
pends on the affected organs, including lipoatro-
phy, lactic acidosis, peripheral neuropathy, he-
patic steatosis, myopathy, cardiomyopathy, pan-
creatitis, bone marrow suppression, and Fanconi
syndrome.
Hepatic failure with refractory lactic acidosis is
the most serious disease complication related to
mitochondrial dysfunction. Stavudine, particu-
larly when associated with didanosine, and less
frequently zidovudine, has been associated with
this clinical presentation.
Didanosine is involved in a rare, but serious, com-
plication: non-cirrhotic portal hypertension. 
Given the known association between NRTI (timi-
dine analogues and d-drugs) and mitocondrial
toxicities, it has been hypothesised that NRTI-
sparing regimens could reduce mitochondrial
dysfunction.
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Pre-emptive or reactive switching from thymi-
dine analogues (stavudine or zidovudine) to al-
ternative nucleoside analogue agents or to an NR-
TI-sparing regimen has resulted in reduced risk
or reverse mitochondrial toxicity.
Statements
– PI/r-based LDR are not indicated for the treat-
ment of HIV patients with CVD or at high risk
for CVD.
– PI/r-based LDR strategy may be considered in
a subset of patients at risk for CVD not show-
ing metabolic alteration under frequent mon-
itoring (CIII).
– PI/r-based LDR can be an option in HIV/HCV
co-infected patients with co-morbidities (BIII).
– PI/r-based LDR can be an option in HIV/HCV
co-infected patients treated with IFN + RBV
(BIII).
– In patients with non-alcoholic fatty liver dis-
ease (NAFLD) and co-morbidities contraindi-
cating the use of NRTI, a PI/r-based LDR reg-
imen could be considered (BIII).
– TDF/3TC, TDF/FTC, TDF and entecavir-spar-
ing regimens are contraindicated in HBsAg
positive or HBcAb and HBV-DNA positive pa-
tients (AII).
– A PI/r-based LDR strategy can be considered
in the subset of patients with increased risk of
or with overt kidney disease and:
• TDF exposure especially in combination
with PI/r (AII).
• Co-morbidities or genetic predispositions
(BII).
• Patients with overt kidney disease (AII).
• Patients with eGFR between 60-90 ml/min
(BII).
• Patients with unmodifiable risk factors (BII).
– A PI/r-based LDR strategy can be considered
in the subset of patients at increased risk of
osteoporosis or osteoporotic fractures and:
• TDF exposure especially in combination
with PI/r (AII).
• Co-morbidities or genetic predispositions
(BII).
• Patients with osteoporosis (AII).
• Patients with osteopenia (BII).
• Patients with unmodifiable risk factors or
with increased turnover markers (BII).
– PI/r-based LDRs could prevent worsening and
partially revert lipoatrophy (AI).
– PI-based LDRs do not appear to reduce lipo-
hypertrophy (BII).
– PI/r-based LDRs may prevent mitochondrial
toxicity (AII).
Neurocognitive aspects
PI/r monotherapy should be able to suppress HIV
replication in all body compartments, although
not all PIs behave the same, since 2 subjects
showed CNS viral escapes. In the MONOI study,
of the 112 participants randomised to receive
DRV/r BID, 2 developed neurological symptoms
compared with none amongst the 113 patients
randomised to continue with their current
HAART. In these 2 patients, the CSF demon-
strated elevated HIV-RNA levels, 330 and 580
cp/mL respectively, whereas plasma HIV-RNA lev-
els were suppressed.
An LDR might be suboptimal in inhibiting CNS
infection, due to low drug levels in the infected
cells (potential low penetration through the
blood-brain barrier of individual drugs). This
could be of particular concern in patients with a
history of HIV encephalitis, since this condition
might be associated with the presence of a sig-
nificant virus reservoir in brain macrophages. 
However, a study evaluating neurocognitive im-
pairment in patients before and after switching
from first-line non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) to second-line LPV/r-con-
taining regimens (LPV/r-based monotherapy or
TDF/3TC/LPV/r) showed a significant NCI im-
provement in both arms with a residual incidence
of neurocognitive impairment after switching to
LPV/r less than 7% and this rate did not differ
with the study arms.
In a recent cross-sectional study in HIV-infected
patients on LPV/r-HAART or LPV/r monothera-
py, during at least 2 years, while maintaining plas-
matic viral load <50 copies/mL, the proportion
of patients with complete virological suppression
in CSF (ultrasensitive HIV-1 RNA <1 copy/mL)
was similar between LPV/r monotherapy and
LPV-HAART groups. In addition, neurocognitive
functioning proved mildly better (close to statis-
tical significance) in patients on LPV/r monother-
apy than in patients on LPV-HAART.
Darunavir CSF concentrations in patients taking
the 800/100 once-daily or the 600/100 twice-dai-
ly dosage of the drug are different: recent data
show that darunavir and ritonavir dosing not on-
The Less Drugs Regimens (LDRs) therapy approach in HIV-1 269
ly significantly affects CSF concentrations, but al-
so the extent of drug penetration into CSF in the
once-daily dosage.
Statements
– Although PI/r monotherapy could favour a re-
duced HIV load in CSF, this strategy is not in-
dicated for use in naïve patients, due to in-
sufficient systemic efficacy (AI) and lack of ev-
idence on the long-term risk of effective HIV
suppression in CSF and risk of neurocogni-
tive impairment (AIII). In naïve patients, when
triple therapy is contraindicated (e.g. toxici-
ties, RT resistance), an LDR based on dual
therapy only can be considered (CII).
– In neuroasymptomatic patients who start
cART, if an LDR dual regimen is indicated,
combination should contain two drugs with
high-ranking CNS penetration/effectiveness
(CPE) at a CD4 level between 350 and 200
cells/mm3, (BIII) or <200 cells/mm3 (AIII).
– In neuroasymptomatic HIV-patients showing
virological suppression, a LDR regimen can
be administered (BI). When PI/r monothera-
py is used Lopinavir/r (400/100 BID)- and
Darunavir/r (600/100 BID)-based LDR regi-
mens are those offering the greatest potential
for success for neuroprotection (BIII).
– PI/r monotherapy, for CNS protection, should
be limited to patients without previous PI fail-
ures, who are highly compliant, with a viral
suppression for >12 months and CD4+ nadir
>100 cells/mm (AII).
– Neurological monitoring, plasma testing for
resistance and drug concentration, and, where
applicable, CSF examination for VL, resist-
ance and drug concentration, is recommend-
ed when virological failure occurs during PI/r
monotherapy (BII). 
– In neuroasymptomatic patients with virolog-
ical failure, LDR may be used exclusively in
dual regimens, based on full activity by re-
sistance/tropism tests (AII).
– For this statement, ANI patients are considered
as neuroasymptomatic patients, because, at this
point, there is inadequate evidence indicating
that ANI would progress to symptomatic forms.
LDR can be employed following the same rec-
ommendations as for asymptomatic patients
(AIII). Special attention should be dedicated to
the possibility of CSF escape (AII). 
– LDRs should be avoided in patients who are
neurologically symptomatic or have previously
HIV-related symptomatic neurocognitive im-
pairment (AII).
Patient-physician LDR communication
needs
In recent years, the paternalistic model that his-
torically characterised the relationship between
physicians and their patients has fully evolved in-
to a modern model in which the patient’s role in
his/her own medical care is more central than in
the past. Patient involvement in this context has
therefore become an increasingly important area
of research in many chronic diseases.
Studies have shown that patients who state a
greater involvement in their medical care are
more satisfied with their physician, state a better
understanding, reassurance, perceived control
over their illness and experience improvements
in their medical conditions. In particular, PLWH
(People Living with HIV) are historically well-in-
formed about treatment issues: the patient-physi-
cian relationship is one of the most important
sources of information, but the Internet and PAGs
(Patient Association Groups) are valuable alter-
natives commonly used by patients.
Therefore, exploring the specific contents of pa-
tient-physician communication when evaluating
an LDR approach, is both an innovative field and
an essential need, in that it must be added to the
normal contents of standard HIV-1 communica-
tion.
Statements
There are common general issues, regardless of
the setting in which an LDR approach is consid-
ered, that are highly recommended for discus-
sion in a dedicated patient-physician meeting.
– Tailoring antiretroviral therapy and treatment
of HIV-1 in a long-term perspective: modifying
the regimen according to patient needs at cer-
tain times in his/her life, to be decided on ac-
cording to clinical presentation and/or to pre-
vent possible future clinical complications, as
well as to meet patient needs as regards
lifestyle. Changing treatment should not be
considered a ‘problem’, but rather an ‘oppor-
tunity’ and ‘smart management’ of a life-last-
ing disease (AIII).
– Information on the LDR definition in HIV-1
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and about the pros and cons of an ‘unconven-
tional strategy’: exploring the reasons for con-
sidering LDR, also including scientific infor-
mation, according to the individual patient’s
skills, and the necessary updates between a
past and a present vision of HIV treatment
management (AIII).
– Explaining the difference between “simplified
HIV maintenance-suppression drug regimen”
and “simplification”. The use of a schematic
simplification (i.e. fewer than 3 drugs) should
be perceived as an important opportunity for
achieving the maximum therapeutic result with
the minimum therapeutic effort, by decreasing
the drug pressure on the virus and stressing the
advantage of taking less medication, even if this
could mean ‘taking more pills more times’ (AI-
II). For patients who are particularly concerned
about pill burden but who are in favour of the
LDR strategy, a co-formulated PI with a PK en-
hancer could also be considered (BIII). 
– Dealing with patient stress regarding treat-
ment switches: in some cases of current ARV
regimens, both the application of an LDR
maintenance strategy and the management of
eventual virological failure in this setting do
not imply a risk of new side-effects or toxici-
ty (AIII). Reassuring the patient of possible
consequences: in the event of virological fail-
ure, irreversible consequences are rare and
‘specific strategies’ for re-establishing unde-
tectability are available; discussing the proce-
dures with him/her (AIII).
– Evaluating the importance of adherence: op-
timal adherence should be the preliminary
condition for considering LDR (AII). In any
case, close monitoring of adherence is highly
recommended (AI). Adherence support meas-
ures, such as reminders or pill boxes, could
be suggested (BIII).
– Sharing the strategy by reaching an agree-
ment: discussing it (according to the individ-
ual patient’s skills), exploring the patient’s mo-
tivation and assessing the patient’s under-
standing as regards his/her situation – fo-
cussing particularly on specific populations
(i.e. migrant people, prisoners, the elderly,
drug-users) that could need tailored attention
to facilitate the communication process.
Scheduling regular feedback meetings could
be recommended (AIII).
– Providing information on specific diagnostic
tools/monitoring intensification: discussing
with the patient all possible issues that could
involve daily life, such as the need to intensi-
fy clinical controls, adherence assessments
and blood draws for the monitoring of viro-
logical suppression (AIII).
– Reassuring the patient that the reason for
choosing an LDR strategy is not based on cost-
related issues (AIII). Some LDRs could also
involve a reduction in the global drug cost: the
issue of costs seldom arises during patient-
physician meetings, but it might be suggest-
ed (if applicable) to mention the favourable
impact of LDR on healthcare system costs (CI-
II), accordingly on the patient-physician rela-
tionship. Discussion should be tailored de-
pending on the patient’s capacity to under-
stand and share the importance of a global
sense of responsibility on this issue (BIII).
PharmacoEconomics
Since the introduction of HAART therapies well-
documented evidence has demonstrated that the
predicted survival years for patients diagnosed
with HIV-1 has continued to increase which has
also resulted in an increase in health resource ab-
sorption.
In this setting, another important issue is the im-
pact of long-term toxicity. Although no data or in-
formation regarding the economic issues relating
to this field have been studied, this could change
the absorption of resources and increase costs,
particularly in terms of the economic need to di-
agnose and cure the corresponding complications.
The possibility of reducing toxicity with the im-
plementation of LDRs may also reduce the eco-
nomic burden of these complications, thereby
freeing up economic resources that could be used
to treat a larger number of HIV-infected patients.
Moreover, some LDRs regimens sensibly reduce
the costs of prescribed drugs by definition.
All these considerations make it essential to ex-
amine potential LDRs, also evaluating the mon-
etary impact and the sustainability of the imple-
mentation of this new treatment alternative in
the third cART era.
Statements
– The reduction of the number of drugs admin-
istered to patients with the implementation of
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an LDR strategy, for specific selected cate-
gories of HIV-positive subjects and for partic-
ular LDR regimens, could be a cost-effective
perspective strategy that should be considered
(BIII). More specific data are required.
– When standard therapies show reasonable
similar efficacy in comparison with LDR, the
economic criteria of resource optimisation
should be taken into consideration in the con-
text of simplification strategy (BIII). More spe-
cific data are required.
Final Remarks
Simplification of a suppressive triple antiretrovi-
ral therapy to LDR has demonstrated safety and
efficacy in a high proportion of stable patients.
The key rationales behind regimen simplification
are to improve the patient’s quality of life and to
maintain long-term compliance, without en-
hancing the risk of virological failure. 
LDRs offer the potential advantages of a de-
creased risk or reversal of toxicities associated
with the use of nucleoside analogue reverse tran-
scriptase inhibitors (NRTIs). Furthermore, LDRs
offer the advantage to maintain future active
treatment options in a long perspective strategy
for the management of HIV disease.
The use of high genetic barrier antiretroviral
drugs (basically, PIs/r) in dual NRTIs-sparing reg-
imens or in monotherapy regimens minimises
the selection of drug-resistant HIV variants. 
Due to the frequency of the citations in the text, the
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